Project Title
Tumor-Infiltrating Lymphocyte Therapy for High-Risk Solid Tumors
Layman’s summary
High-risk types of malignant solid tumors in children (pediatric malignant solid tumors, pMST) have poor long-term cure rates, and new treatments are needed. Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) involves removal and growth and reinfusion of immune cells from a patient’s tumor back to the patient. This is a Phase I clinical trial of TIL-ACT in high-risk pMST to prove its safety and feasibility in children and report on responses seen with this therapy.
Jonathan Metts
This Project By The Numbers
